Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 570

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 7
Chunk 570
---
 our business combination or because we become obligated to redeem a significant
number of our public shares upon completion of our business combination, in which case we may issue additional securities or incur debt
in connection with such business combination.

14

Going Concern

In connection with our assessment
of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”)
2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined
that the mandatory liquidation and subsequent dissolution raises substantial doubt about our ability to continue as a going concern within
one year after the date that the financial statements are issued. No adjustments have been made to the carrying amounts of assets or liabilities
should we be required to liquidate.

Off-Balance Sheet Financing Arrangements

We have no obligations, assets or liabilities,
which would be considered off-balance sheet arrangements as of December 31, 2024. We do not participate in transactions that create relationships
with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established
for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements,
established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

Contractual Obligations 

We do not have any long-term debt, capital lease
obligations, operating lease obligations or long-term liabilities, other than to pay the sponsor $10,000 per month for office space, and
administrative and support services pursuant to an administrative services agreement. Upon completion of the initial business combination
or our liquidation, the administrative services agreement will terminate, and we will cease paying these monthly fees.

The underwriters were entitled to a
cash underwriting discount of $0.05 per Unit, or 0.5% of the gross proceeds of the Initial Public Offering, or $1,150,000 in the aggregate,
paid at the closing of the Initial Public Offering and the over-allotment close. In addition, the underwriters are entitled to a deferred
fee of $0.30 per Unit, or 3.0% of the gross proceeds of the Initial Public Offering, or $6,900,000 in the aggregate, of which 25.0%
will be adjusted net of redemptions (i.e., for purposes of calculating the deferred underwriting commission net of redem